Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000019617-25-000296
Filing Date
2025-03-06
Accepted
2025-03-06 10:52:50
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 4638
  Complete submission text file 0000019617-25-000296.txt   6702
Mailing Address 383 MADISON AVENUE NEW YORK NY 10017
Business Address 383 MADISON AVENUE NEW YORK NY 10017 2122706000
JPMORGAN CHASE & CO (Filed by) CIK: 0000019617 (see all company filings)

EIN.: 132624428 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 6021 National Commercial Banks
(CF Office: 02 Finance)

Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Subject) CIK: 0001479290 (see all company filings)

EIN.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-88023 | Film No.: 25714046
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)